These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 17566047)
21. Inflammatory bowel disease: what is new? Marteau P; Daniel F; Seksik P; Jian R Endoscopy; 2004 Feb; 36(2):130-6. PubMed ID: 14765310 [TBL] [Abstract][Full Text] [Related]
22. Investigating young adults with chronic diarrhoea in primary care. Chapman TP; Chen LY; Leaver L BMJ; 2015 Feb; 350():h573. PubMed ID: 25716699 [No Abstract] [Full Text] [Related]
23. Faecal calprotectin: a new marker for Crohn's disease? Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438 [TBL] [Abstract][Full Text] [Related]
24. Clinical study of the relationship between inflammatory bowel diseases and colorectal neoplasms. Zhao YJ; Yuan YZ J Dig Dis; 2009 May; 10(2):113-7. PubMed ID: 19426393 [TBL] [Abstract][Full Text] [Related]
25. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. Yang GY; Taboada S; Liao J Methods Mol Biol; 2009; 511():193-233. PubMed ID: 19347299 [TBL] [Abstract][Full Text] [Related]
26. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Söderlund S; Granath F; Broström O; Karlén P; Löfberg R; Ekbom A; Askling J Gastroenterology; 2010 May; 138(5):1697-703. PubMed ID: 20167217 [TBL] [Abstract][Full Text] [Related]
27. Calprotectin testing in the community. Wassell J Ann Clin Biochem; 2011 Jan; 48(Pt 1):1-2. PubMed ID: 21273635 [No Abstract] [Full Text] [Related]
28. Surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right? Bernstein CN Gut; 2008 Sep; 57(9):1194-6. PubMed ID: 18719132 [No Abstract] [Full Text] [Related]
29. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Poullis A; Foster R; Shetty A; Fagerhol MK; Mendall MA Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):279-84. PubMed ID: 14973103 [TBL] [Abstract][Full Text] [Related]
30. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Lundberg JO; Hellström PM; Fagerhol MK; Weitzberg E; Roseth AG Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):96-102. PubMed ID: 16265127 [TBL] [Abstract][Full Text] [Related]
31. Cancer surveillance in inflammatory bowel disease: new molecular approaches. Risques RA; Rabinovitch PS; Brentnall TA Curr Opin Gastroenterol; 2006 Jul; 22(4):382-90. PubMed ID: 16760754 [TBL] [Abstract][Full Text] [Related]
32. [Measurement of calprotectin in faeces]. Jahnsen J; Røseth AG; Aadland E Tidsskr Nor Laegeforen; 2009 Apr; 129(8):743-5. PubMed ID: 19373299 [TBL] [Abstract][Full Text] [Related]
38. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Stange EF Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748 [TBL] [Abstract][Full Text] [Related]
39. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]